An observational study in Prostate Cancer, sponsored by Libbs Farmacêutica LTDA. Completed at 1 site in Brazil. Open to male participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-08-02.
Sponsored by Libbs Farmacêutica LTDA · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 134 studies in Prostatic Neoplasms with a site in Brazil — 24 open to participants now, 54 under way, 31 of them phase 3. Prostatic Neoplasms · Brazil.
Among the 134 studies in Prostatic Neoplasms with a site in Brazil, this one is the 11th largest by enrollment of the 18 observational ones that give a count, is one of 6 that started in 2021, is one of 18 observational ones, and was the 93rd registered.
7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →24 of the 134 studies in Prostatic Neoplasms with a site in Brazil are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Brazil, United States, Austria and 18 more countries
Ages 18+ · Men only
Instituto do Cancer do Estado de São Paulo · Sites in Brazil
Ages 18+ · Men only
AstraZeneca · Sites in Brazil, United States, Australia and 21 more countries
Ages 18+ · Men only
University of Sao Paulo · Sites in Brazil
Ages 40+ · Men only
BioNTech SE · Sites in Brazil, United States, Australia and 7 more countries
Ages 18+ · Men only
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
134 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 24 · Phase 3 63 · Phase 4 6
First in 2003; this study’s year is marked. 6 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 280 is above the median of 200 across 1,312 observational studies indexed under Prostatic Neoplasms.
Median enrollment 670 across the 113 interventional studies, 341 across the 18 observational. Of the 67 that completed or were terminated, 39 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
94 of 134 have an industry lead sponsor. The 10 most frequent:
Libbs Farmacêutica LTDA is the lead sponsor of 10 studies on the registry; 2 are open to participants now.
Libbs Farmacêutica LTDA has 1 study filed under Prostatic Neoplasms — fewer than ten, so there is no comparison to draw.
14 of the studies in Prostatic Neoplasms with a site in Brazil that are under way reach primary completion within a year, 8 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03767244Phase 3Janssen Research & Development, LLCA Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy | 2026-12-01 |
| NCT06551324Phase 3PfizerA Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1). | 2027-02-28 |
| NCT02531516Phase 3Aragon Pharmaceuticals, Inc.An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS | 2027-03-01 |
| NCT03574571Phase 3Memorial Sloan Kettering Cancer CenterA Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer | 2027-04-01 |
| NCT05794906Phase 3BayerA Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies | 2027-07-30 |
Add all 14 to your calendar (.ics) → With an account.
Among the 134 studies in Prostatic Neoplasms with a site in Brazil, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Analyze, through an online questionnaire, the knowledge and practice about the prevention and detection of prostate cancer in male employees of a pharmaceutical company.
In Brazil, there are still few published and current studies that explore man's attention and awareness of health. Historically, women attend medical appointments and perform routine tests more frequently than men. For this is very important Analyze, through an online questionnaire, the knowledge and practice about the prevention and detection of prostate cancer in male employees of Libbs Farmacêutica (a pharmaceutical company in Brazil).
As this is a non-probabilistic or convenience (non-random) sampling, the sample size calculation is not applicable. Today there are about 1500 male employees at Libbs Pharmaceuticals and all will be invited to participate in the survey. Answers obtained from all questionnaires filled in their entirety will be included for analysis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All volunteer male employees of Libbs Pharmaceuticals residing in all Brazilian regions will participate in this research.An online questionnaire will be applied to assess research subjects understanding of prostate cancer and health habits.
Behavioral: questionare online application
questionare online application
Evaluation of Knowledge and Practice About Prostate Cancer e Healthy Habits
Assess the subjects knowledge and practice in relation to educational campaigns aimed at prostate cancer.All the information wil be collected using a questionnaire previously approved by the ethics committee.
Time frame: 1 month
Ran from Jun 2021 to primary completion in Jul 2022, 13 months.
Of 109 industry-sponsored observational studies under Prostatic Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 65. This study's 13 months is below that.
Counting every sponsor, half of 651 studies reached it within 60 months; a quarter within 28 and three quarters within 141.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Libbs Farmacêutica LTDA